EUVIMEDEUVIMED entdecken
Crossref

Deucravacitinib (Sotyktu) for Plaque Psoriasis

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1670b ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Psoriasis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved deucravacitinib (Sotyktu – BMS), an oral tyrosine kinase 2 (TYK2) inhibitor, for once-daily treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is the first selective TYK2 inhibitor to be approved in the US for any indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisHumansSeverity of Illness IndexTreatment OutcomeAnti-Inflammatory Agents, Non-SteroidalHeterocyclic Compounds

Stichwörter der Autor:innen

GengrafNeoralOtezlaSoriataneSotyktuTNF inhibitorsactiretinadverse effectsapremilastcyclosporinedeucravacitinibdosagedrug interactionsefficacylactation

Substanzen

Anti-Inflammatory Agents, Non-SteroidaldeucravacitinibHeterocyclic Compounds

Zitieren

APA

(2023). Deucravacitinib (Sotyktu) for Plaque Psoriasis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1670b

Vancouver

Deucravacitinib (Sotyktu) for Plaque Psoriasis. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1670b

BibTeX
@article{euvimed2023,
  title = {Deucravacitinib (Sotyktu) for Plaque Psoriasis},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1670b}
}
Kostenlos starten →